Table 1 Basic characteristics of included studies
References | Country | Design | Recruitment period | Number of patients | Inclusion criteria | HR (lower CI-upper CI) | Follow-up time (month) | ||
|---|---|---|---|---|---|---|---|---|---|
IMNI | Non-IMNI | OS | DFS | ||||||
Wang [13] | China | RCS | 2007–2010 | 390 | 482 | pBC | 0.82 (0.59–1.15) | 0.54 (0.41–0.72) | 98 |
Luo [14] | China | RCS | 2005–2013 | 236 | 261 | Stage II–III | 0.62 (0.37–1.03) | 0.65 (0.46–0.93) | 64 |
Thorsen [15] | Denmark | PCS | 2003–2007 | 1492 | 1597 | N + | 0.82 (0.72–0.94) | – | 107 |
Kim [16] | Korea | RCS | 2001–2009 | 284 | 237 | Stage II–III | 0.51 (0.26–1.01) | 0.58 (0.34–1.00) | 71 |
Yadav [17] | India | RCS | 1978–1996 | 153 | 166 | Stage II–III | 0.89 (0.60–1.30) | 0.35 (0.22–0.55) | 203 |
Aleknavičius [18] | Lithuania | RCS | 1987–1997 | 165 | 268 | Tumor in central/medial | 0.75 (0.55–1.01) | 0.67 (0.46–0.99) | 102 |
Courdi [19] | France | RCS | 1975–2008 | 489 | 1141 | N − | 0.99 (0.81–1.22) | 1.04 (0.88–1.23) | 154 |
Chang [20] | Korea | RCS | 1994–2002 | 197 | 199 | Stage II–III | 0.91 (0.64–1.28) | 0.7 (0.52–0.96) | 98 |
Hennequin [21] | France | RCT | 1991–1997 | 672 | 662 | N + Tumor in central/medial | 0.95 (0.80–1.13) | – | 103 |
Olson [22] | Canada | RCS | 2001–2006 | 1000 | 1413 | N + T3/4N0 | 0.95 (0.78–1.15) | – | 74 |
Stemmer [23] | Israel | NRCT | 1994–1998 | 67 | 33 | Stage II–III | 0.48 (0.19–1.21) | 0.44 (0.18–1.08) | 77 |
Obedian [24] | America | RCS | 1970–1990 | 535 | 411 | Breast conservation surgery | 1.56 (1.10–2.22) | – | 156 |